TD Asset Management
CHRS icon

TD Asset Management’s Coherus Oncology CHRS Stock Holding History

TD Asset Management’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-16,271
Closed -$228K – 1432
2018
Q2 		$228K Hold
16,271
– – ﹤0.01% 1377
2018
Q1 		$180K Buy
16,271
+600
+4% +$6.56K ﹤0.01% 1320
2017
Q4 		$138K Sell
15,671
-8,100
-34% -$86.7K ﹤0.01% 1315
2017
Q3 		$317K Sell
23,771
-2,000
-8% -$26.5K ﹤0.01% 1225
2017
Q2 		$370K Sell
25,771
-5,561
-18% -$107K ﹤0.01% 1233
2017
Q1 		$663K Sell
31,332
-3,400
-10% -$83.6K ﹤0.01% 1143
2016
Q4 		$978K Buy
34,732
+1,900
+6% +$53.2K ﹤0.01% 1032
2016
Q3 		$879K Buy
+32,832
New +$896K ﹤0.01% 1033

Other funds holding CHRS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HP
Hound Partners New York $799M AUM 9.54% 1-Year Est. Return

TD Asset Management's CHRS Position: Q3 2018 in Review

TD Asset Management sold out of Coherus Oncology (CHRS) in Q3 2018, closing a stake of 16,271 shares — an estimated $228K sold.

TD Asset Management first reported a position in CHRS in Q3 2016 and held it in 8 quarters. The position peaked at $978K in Q4 2016. 109 funds tracked by Wall St. Rank hold CHRS as of Q3 2018.

  • TD Asset Management reported no remaining Coherus Oncology position as of Q3 2018 after selling out during the quarter.
  • TD Asset Management sold 16,271 Coherus Oncology shares in Q3 2018, an estimated $228K.
  • TD Asset Management first reported a position in Coherus Oncology in Q3 2016 and held it in 8 quarters.
  • TD Asset Management's Coherus Oncology position peaked at $978K in Q4 2016.
  • 109 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2018.

Based on TD Asset Management's 13F filing for Q3 2018, filed 1 Nov 2018.